Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases - PubMed (original) (raw)
Randomized Controlled Trial
. 2020 Nov;43(11):2859-2869.
doi: 10.2337/dc20-1890. Epub 2020 Sep 16.
Affiliations
- PMID: 32938746
- DOI: 10.2337/dc20-1890
Randomized Controlled Trial
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
Yan Xie et al. Diabetes Care. 2020 Nov.
Abstract
Objective: To examine the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1), dipeptidyl peptidase 4 inhibitors (DPP-4), and sulfonylureas on risk of kidney outcomes among people with type 2 diabetes.
Research design and methods: U.S. veterans initiated on SGLT2i (n = 18,544), GLP-1 (n = 23,711), DPP-4 (n = 39,399), or sulfonylureas (n = 134,904) were followed for up to 3 years to evaluate the risk of the composite outcome of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease (ESKD), or all-cause mortality. Risks were estimated using survival models adjusted for predefined covariates as well as covariates identified by a high-dimensional variable selection algorithm through application of generalized propensity scores.
Results: Compared with those treated with sulfonylureas, treatment with SGLT2i, GLP-1, and DPP-4 was associated with a lower risk of the composite outcome (hazard ratio 0.68 [95% CI 0.63, 0.74], 0.72 [0.67, 0.77], and 0.90 [0.86, 0.95], respectively). While we did not observe a statistically significant difference in risk between the SGLT2i and GLP-1 arms (0.95 [0.87, 1.04]), both SGLT2i and GLP-1 had a lower risk of the composite outcome than DPP-4 (0.76 [0.70, 0.82] and 0.79 [0.74, 0.85], respectively). Analyses by eGFR category suggested that compared with the sulfonylurea arm, those in the SGLT2i and GLP-1 arms exhibited a lower risk of the composite outcome in all eGFR categories, including eGFR <45 mL/min/1.73 m2. Compared with DPP-4, both SGLT2i and GLP-1 exhibited a reduced risk of the composite outcome in eGFR <90 to ≥60, <60 to ≥45, and <45 mL/min/1.73 m2.
Conclusions: In type 2 diabetes, treatment with SGLT2i or GLP-1 compared with DPP-4 or sulfonylureas was associated with a lower risk of adverse kidney outcomes.
© 2020 by the American Diabetes Association.
Similar articles
- Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, Marsolo K, Shah RC, Jones WS, Gordon H, Hwang W, Ayoub I, Ford D, Chamberlain A, Rao A, Fonseca V, Chang A, Ahmad F, Hung A, Hunt K, Butler J, Bosworth HB, Pagidipati N. Edmonston D, et al. J Am Coll Cardiol. 2024 Aug 20;84(8):696-708. doi: 10.1016/j.jacc.2024.06.016. J Am Coll Cardiol. 2024. PMID: 39142723 - Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ, Wu CY, Jenq CC, Lee TH, Tsai CY, Tu HT, Huang YT, Yen CL, Yen TH, Chen YC, Tian YC, Yang CW, Yang HY. Chen JJ, et al. JAMA Netw Open. 2022 Mar 1;5(3):e221169. doi: 10.1001/jamanetworkopen.2022.1169. JAMA Netw Open. 2022. PMID: 35254430 Free PMC article. - The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS, Lee JK, Hung CS, Chen WJ. Lin DS, et al. Diabetologia. 2021 Dec;64(12):2676-2686. doi: 10.1007/s00125-021-05529-w. Epub 2021 Sep 18. Diabetologia. 2021. PMID: 34536085 Review.
Cited by
- Proteome-wide mendelian randomization identifies novel therapeutic targets for chronic kidney disease.
Zhao P, Li Z, Xue S, Cui J, Zhan Y, Zhu Z, Zhang X. Zhao P, et al. Sci Rep. 2024 Sep 27;14(1):22114. doi: 10.1038/s41598-024-72970-3. Sci Rep. 2024. PMID: 39333727 Free PMC article. - Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors.
Choi T, Xie Y, Al-Aly Z. Choi T, et al. Commun Med (Lond). 2024 Sep 11;4(1):179. doi: 10.1038/s43856-024-00599-4. Commun Med (Lond). 2024. PMID: 39261630 Free PMC article. - Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Diabetologia. 2024 Aug 23. doi: 10.1007/s00125-024-06251-z. Online ahead of print. Diabetologia. 2024. PMID: 39177691 - GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
Huang T, Bosi A, Faucon AL, Grams ME, Sjölander A, Fu EL, Xu Y, Carrero JJ. Huang T, et al. JAMA Intern Med. 2024 Aug 12:e243806. doi: 10.1001/jamainternmed.2024.3806. Online ahead of print. JAMA Intern Med. 2024. PMID: 39133509 - Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea.
Lee HK, Jang HY, Kim IW, Oh JM. Lee HK, et al. J Cancer Res Clin Oncol. 2024 May 20;150(5):266. doi: 10.1007/s00432-024-05800-8. J Cancer Res Clin Oncol. 2024. PMID: 38769166 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous